What is a "reach through? Let me paint the picture. Company A licenses technology to Company B. Company B then sublicenses to Company C. Under a reach-through provision, Company B…
After ~six months of integrating AI into our workflows at Lacerta Bio (plus building a few custom tools for ourselves and our clients), I've developed what I call the "intern-to-partner…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Ownership and Inventorship Ambiguity Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those…
A Five-Part Series on AI Drug Discovery Valuation Challenges Introduction I have no idea. That was my brilliant, insightful, memorable, put this on a t-shirt answer to the question posed…
In every industry, revenue is driven by a simple equation: Revenue = (Price per Unit) × (Units Sold) For most sectors, both levers are available. A company can raise prices,…
Poor Louie... Poor Louie King Louis XI of France (1423-1483) was an interesting character. At 17, he rebelled against his Father, Charles VII. Later forgiven by papa, he ascended to the…
In almost every out-licensing or investor presentation we see, there is likely a slide that shows the “Total Addressable Market” (TAM). And, it is always a very large number. The…